Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1391)	2/1/1998 10:44:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 2205

Regranex, from J&J, FDA approved gel for venous ulcer. Active chemical is a "tissue growth factor" I do not remember the exact name of the hormone. They are expecting a $500 millions market. (same market for ATIS and ORG, they will have to learn to share). They are not necessarily mutually exclusive treatments. Regranex could theoretically improve ATIS product (or even ORG's one). Since all the products will probably be out then independent research could follow.